参考文献/References:
[1] 刘长征,王浩丹,胡雅儿.实验核医学与核药学.北京:人民卫生出版社,1999.79-80.
[2] Bigott-Hennkens HM, Dannoon S, Lewis MR, et al. In vitro receptor binding assays:general methods and considerations. Q J Nucl Med Mol Imaging, 2008, 52(3):245-253.
[3] Pinyot A, Nikolovski Z, Bosch J, et al. On the use of cells or membranes for receptor binding:growth hormone secretagogues. Anal Biochem, 2010, 399(2):174-181.
[4] Kung MP, Choi SR, Hou C, et al. Selective binding of 2-[125I]iodonisoxetine to norepinephrine transporters in the brain. Nucl Med Biol, 2004, 31(5):533-541.
[5] Choi H, Choi SR, Zhou R, et al. Iron oxide nanoparticles as magnetic resonance contrast agent for tumor inmging via folate receptor-targeted delivery. Acad Radiol, 2004, 11(9):996-1004.
[6] 高振霆,罗海彬,陈莉莉,等.顺十八碳四烯酸荧光探针法研究PPARγ与配体的结合亲和性.中国科学:B辑,2004,34(6):441-448.
[7] Need AB, McKinzie JH, Mitch CH, et al. In vivo rat brain opioid receptor binding of LY255582 assessed with a novel method using LC/MS/MS and the administration of three tracers simultaneously. Life Sci, 2007, 81(17-18):1389-1396.
[8] Poon GM. Explicit formulation of titration models for isothermal titration calorimetry. Anal Biochem, 2010, 400(2):229-236.
[9] Cornelius P, Lee E, Lin W, et al. Design, synthesis, and pharmacology of fluorescently labeled analogs of serotonin:application to screening of the 5-HT2C receptor. J B omol Screen, 2009, 14(4):360-370.
[10] Goswami R, Ponde DE, Kung MP, et al. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters. Nuel Med Biol, 2006, 33(63:685-694.
[11] Atack JR, Eng WS, Gibson RE, et al. The plasma-occupancy relationship of the novel GABAA receptor benzodiazepine site ligand, alpha5IA, is similar in rats and primates. Br J Pharmacol, 2009, 157(5):796-803.
[12] Zeng Z, O’Brien JA, Lemaire W, et al. A novel radioligand for glycine transporter 1:characterization and use in autoradiographic and in vivo brain occupancy studies. Nucl Med Biol, 2008, 35(3):315-325.
[13] Kecskes M, Kumar TS, Yoo L, et al. Novel Alexa Fluor-488 labeled antagonist of the A(2A) adenosine receptor:Application to a fluorescence polarization-based receptor binding assay. Biochem Pharmacol, 2010, 80(4):506-511.
[14] 蒋心惠,周岐新.高效液相色谱法测定硫酸特布他林与红细胞膜表面β2肾上腺素受体结合量.分析化学,2010,38(3):377-380.
[15] 蒋心惠,杨俊卿,周岐新.沙丁胺醇与红细胞膜表面β2-肾上腺素受体结合量的高效液相色谱法测定.分析测试学报,2010,29(8):837-840.
[16] Höfner G, Wanner KT. Competitive binding assays made easy with a native marker and mass spectrometric quantification. Angew Chem Int Ed Engl, 2003, 42(42):5235-5237.
[17] Zepperitz C, Höfner G, Wanner KT. MS-binding assays:Kinetic, saturation, and competitive experiments based on quantitation of bound marker as exemplified by the GABA transporter mGAT1. ChemMedChem, 2006, 1(2):208-217.
[18] Höfner G, Merkel D, Wanner KT. MS binding assays-with MALDI toward high throughput. ChemMedChem, 2009, 4(9):1523-1528.
[19] Emonds KM, Swinnen JV, Mortehnans L, et al. Molecular imaging of prostate cancer. Methods, 2009, 48(2):193-199.
[20] Hou C, Tu Z, Mach R, et al. Characterization of a novel iodinated sigma-2 receptor ligand as a cell proliferation marker. Nucl Med Biol, 2006, 33(2):203-209.
[21] Oya S, Choi SR, Kung MP, et al. 5-Chloro-2-(2’-((dimethylamino) methyl)-4-iodophenylthio) benzenamine:a new serotonin transporter ligand. Nucl Med Biol, 2007, 34(2):129-139.
[22] Lakshmi B, Kung MP, Lieberman B, et al. (R)-N-Methyl-3-(3-(125)Ipyridin-2-yloxy)-3phenylpropan-l-amine:a novel probe for norepinephrine transporters. Nucl Med Biol, 2008, 35(1):43-52.
[23] Bourdier T, Poisnel G, Dhilly M, et al. Synthesis and biological evaluation of N-substituted quinolinimides, as potential ligands for in vivo imaging studies of delta-opioid receptors. Bioconjug Chem, 2007, 18(2):538-548.
[24] Li J, Fish RL, Cook SM, et al. Comparison of in vivo and ex vivo[3H]flumazenil binding assays to determine occupancy at the benzodiazepine binding site of rat brain GABAA receptors. Neuropharmaeology, 2006, 51(1):168-172.
[25] Barth VN, Chernet E, Martin LJ, Need AB, et al. Comparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measured using radiolabeled or nonlabeled raclopride tracer. Life Sci, 2006, 78(26):3007-3012.
[26] Zhu L, Liu J, Kung HF. Synthesis and evaluation of 2-amino-dihydrotetrabenzine derivatives as probes for imaging vesicular monoamine transporter-2. Bioorg Med Chem Lett, 2009, 19(17):5026-5028.
[27] Stadalnik RC, Vera DR. The evolution of (99m)Tc-NGA as a clinically useful receptor-binding radiopharmaceutical. Nucl Med Biol, 2001, 28(5):499-503.
相似文献/References:
[1]李海峰,张晓军,张锦明.多巴胺转运蛋白显像剂11C-β-CFT在帕金森病中的应用研究[J].国际放射医学核医学杂志,2016,40(3):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
Li Haifeng,Zhang Xiaojun,Zhang Jinming.Review of the use of dopamine transporter imaging agent 11C-β-CFT for diagnosing Parkinson disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
[2]范永增,袁耿彪.靶向性纳米药物对肿瘤的应用研究[J].国际放射医学核医学杂志,2010,34(1):16.[doi:10.3760/cma.j.issn.1673-4114.2010.01.004]
FAN Yong-zeng,YUAN Geng-biao.Application of targeting nano-drug for neoplasms[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(6):16.[doi:10.3760/cma.j.issn.1673-4114.2010.01.004]
[3]甘红梅,乔晋萍,孔爱英,等.正电子放射性显像剂代谢及其研究方法进展[J].国际放射医学核医学杂志,2010,34(2):65.[doi:10.3760/cma.j.issn.1673-4114.2010.02.001]
GAN Hong-mei,QIAO Jin-ping,KONG Ai-ying,et al.The progress on researching method and metabolism of positron radiopharmaceutical[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(6):65.[doi:10.3760/cma.j.issn.1673-4114.2010.02.001]
[4]顾涛颖,石洪成.放射性药物治疗肿瘤骨转移性骨痛的作用[J].国际放射医学核医学杂志,2010,34(2):88.[doi:10.3760/cma.j.issn.1673-4114.2010.02.006]
GU Tao-ying,SHI Hong-cheng.The use of radiopharmaceuticals for metastatic bone pain in cancer patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(6):88.[doi:10.3760/cma.j.issn.1673-4114.2010.02.006]
[5]方圣伟,奚望,张宏.分子核医学的发展和应用前景[J].国际放射医学核医学杂志,2009,33(6):321.[doi:10.3760/cma.j.issn.1673-4114.2009.06.001]
FANG Sheng-wei,XI Wang,ZHANG Hong.The developments and applications of molecular nuclear medicine[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(6):321.[doi:10.3760/cma.j.issn.1673-4114.2009.06.001]
[6]彭添兴,吴华.18F-氟脱氧葡萄糖以外新型PET肿瘤显像剂[J].国际放射医学核医学杂志,2007,31(1):9.
PENG Tian-xing,WU Hua.New type PET imaging agent excluding 18F-fluorodeoxyglucose in oncology[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(6):9.
[7]张锦明,田嘉禾,刘伯里.影响PET放射性药物11C甲基化的因素[J].国际放射医学核医学杂志,2006,30(5):271.
ZHANG Jing-ming,TIAN Jia-he,LIU Bo-li.Influence factor on 11C methylation in PET radiopharmaceuticals[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(6):271.
[8]范我.用于肿瘤治疗的放射性药物[J].国际放射医学核医学杂志,2004,28(1):21.
FAN Wo.Radiopharmaceuticals for tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(6):21.
[9]陈璟,吴华.核素炎症显像的研究进展[J].国际放射医学核医学杂志,2003,27(3):107.
CHEN Jing,WU Hua.The development of radionuclide imaging of infection and inflammation[J].International Journal of Radiation Medicine and Nuclear Medicine,2003,27(6):107.
[10]杨建权,李晔,张现忠.基于小分子肽的放射性药物[J].国际放射医学核医学杂志,2003,27(4):157.
YANG Jian-quan,LI Ye,ZHANG Xian-zhnng.Peptide as carrier for diagnosis and treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2003,27(6):157.